Scientific paper - Ressources

Generative AI Empowers the Search for PIM-1 Kinase Inhibitors: unveiling Novel Promising Chemical Entities

Circle Oncodesign Services

Autors :

Christophe Parsy2, Anna Kriukova1, Pascaline Jacquemard2, Maud Jusot1, Quentin Janet2, Nicolas Devaux1, Anthony Martinez2, Christopher Housseman1, Sautet Stephane2, Alexis Denis1, Quentin Perron1, Yann Lamotte2, Brice Hoffmann1

1 IKTOS Company, 2 ONCODESIGN SERVICES

 

Abstract :

In early stage hit-discovery or scaffold-hopping discovery development programs, the primary challenge is to find new chemical matter that is both novel and has exclusive Freedom to Operate (FTO), while also optimizing physico-chemical properties that are important for robust in vivo activity. This is a difficult multi-parameter optimization (MPO) problem, making the drug discovery process complex, expensive, and time-consuming. Traditional screening methods such as virtual screening of large chemical databases have limited success in solving the MPO problem due to exploring only a small section of the chemical space, which lacks diversity and novelty. To address these limitations, a 3D structure-based generative Artificial Intelligence (AI) pipeline was developed, which is focused on solving the MPO problem by identifying new, easily accessible molecules with drug-like characteristics and high activity on the protein targeted. The technology employs deep-learning based de novo design algorithms and is optimized through Reinforcement Learning, based on various factors such as diversity, novelty, quality, synthetic accessibility and 3D scores. This iterative AI-based chemical space exploration generates new chemical structures with optimal 3D scores and physico-chemical properties. Using this approach, novel active compounds for an oncology target (PIM1-kinase) have been successfully identified with high affinity, outside the chemical space of known PIM1-kinase inhibitors. Experimental results indicate good preliminary ADME properties for one of the novel PIM1 compounds, with an IC50<50nM. This represents a significant shift in tackling MPO in early stage drug discovery projects and increases the chances of success while drastically shortening the time for Hit finding.

 

Read the poster

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.